Navitoclax

This experimental, orally active anti-cancer drug is a Bcl-2 inhibitor, similar in action to obatoclax. It has demonstrated potent treatment effects on small cell lung cancer and acute lymphocytic leukemia, and is also utilized in combination therapy for solid tumors.